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ABSTRACT 
 
Introduction: Surveillance patterns in Barrett’s esophagus (BE) are not well 
characterized. Guidelines published between 2002-2008 recommended surveillance 
esophagogastroduodenoscopy (sEGD) at three-year intervals for nondysplastic BE 
(NDBE). We assessed guideline adherence in incident NDBE in a VA-based study. 
 
Methods: At a single VA center, we identified incident cases of biopsy-confirmed NDBE 
between 1/2006-12/2008.  We excluded patients age ≥76 years and those who developed 
BE-associated dysplasia or cancer during follow-up. All sEGDs through 10/2014 were 
documented. Our primary criteria classified cases as guideline adherent if a sEGD was 
performed within 6 months of each expected three-year surveillance interval; in cases 
with ≥2 sEGDs, one sEGD >6 months and ≤1 year outside an interval was allowed if the 
average interval was between 2.5 and 3.5 years. Comorbidity, primary care (PC) 
encounters, presence of long segment BE (LSBE), endoscopist recommendations, and 
Charlson comorbidity index (CCI) were assessed. 
 
Results: We identified 110 patients (96.4% male, 93.6% Caucasian) with mean age 58.9 
± 8.5 years at index EGD. Median follow-up was 6.7 years (range 3.7-8.6). 33 (30.0%) 
cases were guideline adherent; 77 (70.0%) cases were non-adherent, including 52 
(47.3%) with irregular surveillance and 25 (22.7%) with no surveillance. 40 cases (14 
adherent) had 1 sEGD, 36 (18 adherent) had 2, 8 (1 adherent) had 3, and 1 non-adherent 
case had 4. Adherent cases were significantly older (61.5 vs 57.9 years, p=0.04), and 
tended to have more LSBE (33.3% vs 20.8%, p=0.16). There were no differences 
between adherent and non-adherent cases in annual PC encounters (72.7% vs 66.2%, 
p=0.66), CCI ≥4 (15.2% vs 15.6% p=0.95), biopsy-positive sEGDs (75.8% vs 76.6%, 
p=0.92), and any recommendation for subsequent surveillance (81.8% vs 77.9%, p=0.65). 
A logistic regression model using age, CCI, and LSBE showed an independent 
association between adherence and older age (p=0.03). 
 
Conclusions: In a single-center VA cohort, sEGD of NDBE was mostly non-adherent to 
guidelines. Adherent cases were older at baseline with a trend towards more LSBE. A 
larger study is needed to identify medical and social factors associated with adherence or 
non-adherence to surveillance. 
 
 
 
 
 
 
 
 
 
 
 
 
3 
 
INTRODUCTION  
 
 
Barrett’s esophagus is a premalignant condition of the esophagus associated with an 
increased risk of esophageal adenocarcinoma [1-3], and for which endoscopic 
surveillance is recommended.  The guidelines from major gastrointestinal societies 
published between 2002 and 2008 specify a 3-year surveillance interval for non-
dysplastic Barrett’s esophagus (NDBE) [4-6].  In part because of recent data indicating a 
lower-than-expected risk of adenocarcinoma arising from Barrett’s epithelium [7], more 
recent guidelines have extended the surveillance interval to 3-5 years. [8, 9]   
 
While most endoscopists practice endoscopic surveillance for NDBE [10], there is 
considerable variation in surveillance patterns and adherence to guideline 
recommendations [10-16].  Particularly in community practice, adherence to surveillance 
guidelines is low. [14] One multicenter study demonstrated overutilization of endoscopic 
surveillance in NDBE as measured by patient report [17], whereas a previous VA-based 
multicenter study showed that regular surveillance was practiced in only 23% of patients 
who had at least 6 years of follow-up. [18] 
 
Most of the previous studies are limited by reliance on surveys and questionnaires, or by 
a lack of pathology.  In addition, clinical factors (such as severe comorbidity and patient 
age) that might explain deviation from surveillance guidelines are not available.  We 
conducted a single-center VA-based study to assess electronic medical record-based 
adherence to guideline recommendations in biopsy-proven incident NDBE.  The primary 
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aim was to quantify adherence to surveillance guidelines; the secondary aim was to 
identify factors associated with adherence.   
 
METHODS 
 
This study protocol was approved with a waiver of informed consent by the Indiana 
University Institutional Review Board and by the Research Committee at the Richard L. 
Roudebush VA Medical Center in Indianapolis, IN.  We searched the Indianapolis VA’s 
electronic medical record (Computerized Patient Record System [CPRS]) and a linked, 
independent endoscopy database (ProVation, Inc.) to identify all incident cases of NDBE 
diagnosed between January 2006 and December 2008.  Within the ProVation software, 
search queries specifying upper endoscopy with endoscopic findings of BE and 
maneuvers including “Barrett’s biopsies” or “esophageal biopsies” were utilized to 
identify all potential BE cases.  Within the CPRS, ICD-9 and CPT codes were used to 
identify potential incident BE cases.  Codes included ICD-9 code 530.85 for Barrett’s 
Esophagus, and CPT codes 43235, 43236, 43239, 43241-43251, and 43255-43258.   
 
Patient records from ProVation and CPRS were merged using SAS 9.2 to identify the 
total number of unique patients during the study period.  Pathology reports for these 
patients were then manually reviewed.  Patients were included for analysis if they had 
biopsy-confirmed, incident diagnosis of BE during the study period and were younger 
than 76 years of age at the time of diagnosis.   
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We excluded prevalent cases of Barrett’s esophagus, including those diagnosed outside 
our center, as well as patients with any grade of dysplasia or adenocarcinoma diagnosed 
at time of index procedure through the 1st surveillance endoscopy, and patients with no 
further VA encounters after the index diagnosis. 
 
We abstracted data on patient demographics, symptoms, comorbidities, and number of 
primary care (PC) encounters.  Data were also collected on procedural characteristics 
including presence or absence of long-segment BE (LSBE), endoscopist 
recommendations for timing of subsequent surveillance, and biopsy results from 
surveillance exams.  The Charlson-Deyo comorbidity index (CCI) score was calculated 
for each patient. 
 
Index and surveillance endoscopies: 
The index endoscopy refers to the first documented upper endoscopy procedure at the 
Roudebush VA Medical Center with findings of an irregular z-line or BE, and during 
which biopsies of the z-line or esophagus were taken with confirmation of BE.  
Surveillance intervals are defined as 3-year periods between surveillance EGDs (sEGD) 
for BE.  This interval was chosen based on the 2002-2008 ACG and ASGE guidelines [4-
6], which best corresponded to the time frame of our incident cases.  We assumed that 
surveillance practices during the follow-up period most likely reflected these guidelines, 
and that these practices had not yet been significantly impacted by updates to the 
guidelines in 2011 and 2012, which increased acceptable intervals to 3-5 years. [8, 9] 
Surveillance at our center was largely performed using a recall database, where patients 
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were contacted based on an endoscopist’s recommendation at the time of a sEGD and 
pathology review; these recommendations were unlikely to have been modified by 
updates to the guidelines.  
 
All sEGDs had the indication of “follow-up” or “surveillance” of BE, and required 
esophageal biopsies to be taken during the same procedure.  If a procedure was 
performed for an alternate indication but fell within the expected surveillance interval in 
the absence of another sEGD within that interval, and if esophageal biopsies were taken, 
this procedure was considered to be the sEGD corresponding to that interval.   
 
If sEGD was aborted prior to biopsies being taken, or if biopsies were not taken due to 
severe esophagitis, only the subsequent exam with biopsies was counted towards 
surveillance.  If biopsies during sEGD were incomplete or yielded indeterminate biopsy 
results and necessitated a shorter interval follow-up EGD, only the initial sEGD with 
biopsies was counted towards surveillance.   
 
Based on guideline recommendations to repeat the EGD 1 year following the index 
diagnosis of BE [5, 6], we allowed for a single confirmatory endoscopy within 15 months 
of BE index diagnosis (the 1-year confirmatory endoscopy along with a 3-month “buffer” 
period), and did not count this confirmatory endoscopy towards surveillance.  In cases 
without a confirmatory endoscopy, if the first sEGD occurred earlier than 6 months from 
the expected 3-year surveillance interval, we only assessed guideline adherence from this 
point forward to prevent biasing towards over-surveillance.   
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Patient follow-up 
Follow-up was conducted from the date of index diagnosis to the date of the last 
outpatient VA encounter through November 1, 2014.  The total surveillance period was 
determined using the date of the confirmatory endoscopy (or the date of the index 
endoscopy in cases without a confirmatory endoscopy) along with the date of the last 
outpatient VA encounter.  Follow-up was assessed by review of CPRS at our center, and 
VistaWeb to account for other VA centers where the patient may have received medical 
care.    
 
Determining guideline adherence 
For our primary set of criteria, a case was considered adherent to guidelines if each 
sEGD was performed within 6 months (on either side) of the expected three-year 
surveillance interval, and surveillance was not yet overdue by more than 6 months.  In 
cases with more than one sEGD that did not satisfy the preceding criterion, a single 
sEGD up to 1 year outside of the expected interval was accepted as adherent if the total 
number of years per sEGD (total surveillance period/ total number of sEGDs) was ≥ 2.5 
and ≤ 3.5.  Any case not meeting these criteria was considered to be guideline non-
adherent.   Among cases that were guideline non-adherent, we sub-classified cases as 
having no surveillance or irregular surveillance.   
 
We also examined adherence to a secondary, more lenient set of criteria as a type of 
sensitivity analysis, where a case was considered non-adherent if a single sEGD was 
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performed more than 1 year outside of an expected three-year interval, was more than 1 
year overdue, or if two or more sEGDs were performed more than 6 months outside of 
the expected surveillance interval.  All other cases were then considered to be guideline-
adherent.  
 
Data analysis 
Descriptive analyses were conducted using means and standard deviations for continuous 
variables and proportions for categorical and binary variables.  Bivariate analysis was 
performed to test the association of patient and procedural factors with guideline-
adherence.  To determine factors independently associated with adherence / non-
adherence, logistic regression analysis was performed to model the association between 
patient and procedural factors with guideline-adherence.  A bivariate p-value of 0.10 or 
less and clinical judgment were used to select candidate variables for the multiple logistic 
regression equation.  
 
 
RESULTS 
 
A total of 110 patients (96.4% male, 93.6% Caucasian) were included in the analysis 
(Figure 1), with mean age 58.9 ± 8.5 years at index EGD.  Median total follow-up was 
6.7 years (IQR 1.3, range 3.7-8.6) years.  Median duration of the surveillance period was 
6.3 years (IQR 1.6, range 3.7-8.6).  Patient and index procedure characteristics are 
described in Table 1.   
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Using the primary adherence criteria, 33 (30.0%) patients were determined to be 
guideline-adherent; 77 (70.0%) cases were non-adherent, including 52 (47.3% overall) 
with irregular surveillance and 25 (22.7% overall) with no surveillance.  A total of 85 
patients had at least one sEGD performed during the surveillance period, while 45 
patients had at least two sEGDs and 9 had at least three (Figure 2).   
 
Differences between adherent and non-adherent patients are shown in Table 2.  In 
bivariate analysis, adherent patients were older (61.3 vs 57.9 years, p<0.001), and tended 
to have more LSBE (33.3% vs 20.8%, p=0.16). There were no differences in proportions 
with at least an annual PC encounter, CCI score of  ≥ 4, sEGDs with biopsy-positive BE, 
or in recommendation given by the endoscopist for timing of subsequent sEGD.  There 
were also no significant associations between guideline-adherence and any patient 
characteristic, including symptoms at time of index EGD and individual comorbid 
conditions.  
 
The recommended intervals for future surveillance provided by the endoscopist 
performing each sEGD are shown in Figure 3.  Following the index EGD, the 
recommendation was to perform follow-up EGD within 1 year in 77.3% of cases, likely 
reflecting the guideline recommendations to have a confirmatory EGD 1 year after index 
BE diagnosis.  For subsequent surveillance, the endoscopists recommended sEGD at 3-
year intervals for the majority of cases, which followed 2002-2008 guidelines.  The 
observed recommendations did not reflect updated guidelines from 2011 and 2012, as a 
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minority of endoscopists recommended surveillance at 3-5 year intervals.  This lag 
between updated surveillance guidelines and application to practice suggests that the 
updated guidelines had not been widely adopted during the surveillance period, or had 
not yet impacted surveillance practices.   
 
A logistic regression analysis of the association between guideline-adherence and age, 
CCI group, and presence of LSBE showed an independent association between adherence 
and older age (p=0.03; OR 1.06; CI 1.01-1.12).  CCI group (p=0.24) and presence of 
LSBE (p=0.12) were not associated with adherence.  Age and presence of LSBE were 
included in the model based on results from bivariate analysis, and CCI group was 
included due to its perceived impact on real-life surveillance practices.    
 
In sensitivity analysis, we assessed adherence using the more lenient secondary criteria  
and found that the proportion of adherent cases remained in the minority at 41.8%.  In 
addition, while it is unlikely that the ASGE 2012 guidelines [9] had a significant impact 
on surveillance practices during the study period, we applied these guidelines in 
conjunction with the primary criteria to any surveillance interval that potentially could 
have been modified to reflect the updated guideline recommendations; under these 
conditions adherence was 46.4%.   
 
DISCUSSION 
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In this single-center VA-based study of 110 incident cases of biopsy-confirmed Barrett’s 
esophagus, we compared actual surveillance practices with surveillance 
recommendations based on the 2002-2008 guidelines.  We found that the minority of 
cases (30%) were guideline-adherent.  This remained true even when using a more 
lenient set of criteria for quantifying adherence, which intended to allow for greater 
flexibility in scheduling, patient compliance, and other factors that might have delayed 
surveillance.   
 
Over the past decade, a limited number of studies on endoscopic surveillance of BE 
indicate that most gastroenterologists perform surveillance to some degree. [8, 10, 14, 16, 
19] In a survey of mostly U.S. community gastroenterologists, 86% practiced 
surveillance for NDBE [10], while in a recent European survey of mostly university-
based gastroenterologists, 76% practiced surveillance for NDBE. [19] In another large 
survey of 470 North American AGA members, 79% performed surveillance for NDBE 
[16] in accordance with the 2011 AGA guidelines. [8] 
 
Considerable variation has been reported in actual surveillance patterns.  Surveys of 
physicians from the UK [12], France [11], and the Netherlands [20] show that 
surveillance generally follows international guidelines, although it is less consistent in the 
presence of LGD. [12] In a large UK-based survey on the management of BE, wide 
variation was reported in surveillance for specific subgroups (those with LSBE or 
mucosal abnormalities were more likely to be surveyed), surveillance interval, and biopsy 
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protocol.  The majority of gastroenterologists who do not offer surveillance claimed a 
lack of efficacy and the need for stronger evidence for surveillance as the reason. [21] 
 
Another study suggested that endoscopy is over-utilized for surveillance in BE.  In this 
multicenter study, 235 patients with NDBE were given a survey to collect data including 
validated measures of quality of life, symptom severity, cancer risk perception, and 
number of times they underwent surveillance endoscopies.  The investigators presumed 
that all post-diagnosis endoscopies were for surveillance purposes, and found that 
overutilization occurred in 65% of cases using a cutoff of >1 endoscopy per three year 
period.  A trend towards over-surveillance was seen with private insurance, although no 
demographic factors, health behaviors, or symptom severity measures were associated 
with over-surveillance. [17] 
 
Prior VA-based studies have suggested that most veterans do not undergo regular 
surveillance.  El-Serag et al demonstrated that of 4499 patients with a minimum of six 
years follow-up, only 23.0% had regular surveillance, while 26.7% had irregular 
surveillance and 50.3% had no surveillance.  Study limitations include potential 
misclassification of BE and surveillance from use of ICD-9 codes for cohort 
identification and lack of pathology data. [18] In a single VA center without a formal 
surveillance program, 305 (64.6%) of 472 patients diagnosed with BE did not have 
surveillance based on review of medical records; 165 patients underwent surveillance 
with a median surveillance interval of 50 months (range 3-204); 44 patients missed their 
surveillance by 6 months or more, and 23 missed their surveillance by twice the 
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recommended interval of 3 years. [22] Our results add further evidence of under-
surveillance in the veteran population.  
 
Inconsistencies and limitations in reported surveillance practices among prior studies may 
be related to reliance on surveys [11, 12, 16-20], variable inclusion criteria for 
surveillance endoscopies [17, 18, 22], and lack of histologic data [17, 18].  We attempted 
to circumvent these issues and provide a true estimate of endoscopic surveillance by 
clarifying the indication of each endoscopy and measuring actual surveillance frequency 
by reviewing endoscopic records.  We minimized the possibility of misclassifying BE 
cases from over-reliance on coding queries by selecting histologically confirmed cases.  
Finally, we performed sensitivity analysis by using more lenient surveillance intervals to 
avoid biasing the results towards under-surveillance; adherent patients remained in the 
minority, with an absolute difference of 11.8% compared to our primary criteria.     
 
Multiple logistic regression found that older age was independently associated with 
guideline-adherence.  This finding contrasts with that of a previous VA-based study, in 
which El-Serag et al showed that compared to patients with no surveillance, patients with 
at least one sEGD were more likely to be under 65 years of age.  Guideline-adherent 
patients were also somewhat more likely to have GERD, obesity, dysphagia, strictures, 
and less likely to have a high Deyo comorbidity score. [18] Although we hypothesized 
that guideline non-adherence could be explained by increasing comorbid conditions as 
reflected by a higher CCI, this hypothesis was not confirmed by the logistic regression. 
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Despite the low rate of guideline-adherence in our cohort, only a fraction of cases with 
non-adherence could be attributed to a recommendation made by the endoscopist that 
deviated from the guidelines.  At the time of surveillance, the endoscopist recommended 
three-year follow-up for subsequent sEGD in the majority of cases, suggesting that the 
endoscopists generally intended to follow guidelines, but that competing variables − 
including facility-level factors not included in our logistic model − may have impacted 
observed surveillance patterns.  Facility-level variation across multiple VA facilities has 
been shown to influence surveillance, including the finding that patients seen at a smaller 
VA facility (< 87 beds) were more likely to have undergone surveillance. [18] 
 
Our study has important limitations to consider.  Given the observational and 
retrospective nature of this study, we could not account for the contribution of certain 
unobserved factors including patient refusal or noncompliance with surveillance, 
surveillance conducted at non-VA facilities, and undocumented comorbid conditions and 
symptom severity.  In addition, while we considered the intention of endoscopists 
regarding future surveillance based on recommended follow-up intervals, we could not 
account for facility-level factors, including reliance on a recall database and use of an 
open-access system, as is our endoscopy unit.  Finally, our results are based on a cohort 
of veteran patients at a tertiary VA center and may not apply to other health-care settings.   
 
In an open-access endoscopy unit such as ours, lack of adherence may reflect inadequate 
understanding of the surveillance guidelines on the part of the primary care provider.  
However, while patients are often referred for Barrett’s screening by the primary 
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provider, their role in determining the appropriate surveillance interval at our center is 
limited.  This interval is determined by the endoscopist completing the exam, entered into 
a recall database, and documented in the medical record.  Thus, non-adherent 
surveillance less likely reflects the primary provider’s awareness of guideline 
recommendations.  In fact, the primary provider often relies on the endoscopist to 
manage this aspect of a veteran’s care.   
 
If guideline-adherence is truly uncommon in veterans, the reasons for this were not 
elucidated by examination of the medical record and require further study.  The low 
incidence of EAC in NDBE may impact decision-making regarding surveillance on the 
part of both providers and patients.  Future studies should aim to assess adherence to 
surveillance recommendations in the context of updated guidelines, which liberalize 
surveillance to 3-5 year intervals, and should identify the patient-, provider-, and/or 
systems-specific reasons for non-adherence with surveillance guidelines.    
 
In summary, guideline-adherence was observed in the minority of patients in our study of 
veterans with histologically-confirmed BE when considering only true surveillance 
procedures.  In conjunction with prior VA-based studies, our findings may lead to 
heightened awareness for under-surveillance in the veteran population, and provide the 
impetus for establishing quality measures to ensure that guideline-driven endoscopic 
surveillance is considered for all patients with BE.   
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Table 1. Patient and Index EGD Characteristics  
Age at index (mean ± st dev) 58.9 ± 8.5 
Length of follow-up (yrs) [median (range)] 6.7 (3.7-8.6) 
Length of surveillance (yrs) [median 
(range)] 6.3 (3.7-8.6) 
Sex n % 
  Male  106 96.4% 
  Female 4 3.6% 
Race n % 
  White 103 93.6% 
  Black 7 6.4% 
Index procedure 
Indication 
 
  
  GERD/heartburn 37 33.6% 
  Abdominal pain/dyspepsia 16 14.5% 
  Anemia 15 13.6% 
  Dysphagia 13 11.8% 
  Follow-up of esophagitis 5 4.5% 
  GI Bleed 5 4.5% 
  Diarrhea 4 3.6% 
  History liver disease/varices 3 2.7% 
  Nausea ± vomiting 3 2.7% 
  Weight loss 3 2.7% 
  Other 6 5.5% 
Endoscopic finding 
 
  
  Long segment BE 27 24.5% 
  Short segment BE 63 57.3% 
  Irregular Z-line 20 18.2% 
Recommended to repeat EGD in 6 months* 5 4.5% 
Recommended to repeat EGD in 1 year* 72 66.1% 
*For confirmatory EGD  
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Table 2. Comparison of Surveillance-Adherent and -Non-Adherent Patients  
    Adherent  Non-adherent  p-value 
Total number of patients 33 (30.0%) 77 (70.0%)   
Mean age (yrs +/- SD) 61.3 (±7.7) 57.9 (±8.7) <0.001 
Congestive heart failure 1 (3.0%) 6 (7.8%) 0.35 
Chronic pulmonary disease 7 (21.2%) 12 (15.6%) 0.47 
Heartburn 17 (51.5%) 38 (49.4%) 0.84 
Abdominal pain/dyspepsia 8 (24.2%) 22 (28.6%) 0.64 
Dysphagia 10 (30.3%) 14 (18.2%) 0.16 
Mean length of follow-up (years) 6.1 (±1.0) 6.5 (±1.2) 0.21 
Long segment BE 11 (33.3%) 16 (20.8%) 0.16 
Patients with annual PCP encounter 24 (72.7%) 51 (66.2%) 0.66 
sEGDs with biopsy-positive BE (overall) 25 (75.8%) 59 (76.6%) 0.92 
Any recommendation given by 
endoscopist for timing of next sEGD 
27 (81.8%) 60 (77.9%) 0.65 
Charlson-Deyo Comorbidity Index       
  0 16 (48.5%) 27 (35.1%) 
  1 5 (15.2%) 20 (26.0%) 
  2 5 (15.2%) 13 (16.9%) 
  3 2 (6.0%) 5 (6.5%) 
  4+ 5 (15.2%) 12 (15.6%) 
Confirmatory EGD 15 (45.5%) 30 (39.0%) 0.53 
  
Number (%) with positive biopsy 
result for BE 
13 (86.7%) 19 (63.3%) 
0.04 
  
Number (%) recommended to 
repeat sEGD in 3 years by 
endoscopist 
15 (100%) 24 (80.0%) 
0.07 
1st Surveillance EGD 33 (100.0%) 52 (67.5%)   
  
Number (%) with positive biopsy 
result for BE 
24  (72.7%) 39 (75.0%) 
  
  
Number (%) recommended to 
repeat sEGD in 3 years by 
endoscopist 
28 (84.8%) 35 (67.3%) 
  
Number of deaths during follow-up 3 (9.1%) 7 (9.1%) 1.00 
Median follow-up [years (range)] 6.5 (3.7-6.7) 4.3 (3.9-7.0)   
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FIGURE KEY 
 
 
Figure 1: Patient Inclusion 
 
Figure 2: Overall Endoscopic Surveillance Patterns During Follow-Up Period 
 
Figure 3: Endoscopist Recommendation For Timing of Follow-Up EGD 
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      Figure 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
354 patients abstracted from ProVation 455 patients abstracted from CPRS 
515 unique patients identified from CPRS and ProVation 
 
513 with biopsies taken 
 383 biopsy proven BE 
 273 patients excluded: Prior diagnosis (n=208) Age >76 (n=19) Pt not alive for full surveillance interval (n=18) Pt was lost to fup before full surveillance cycle (n=1) Cancer diagnosis at index exam (n=5) Low grade dysplasia (n=16) High grade dysplasia (n=5) Misindication of LGD  during fup (n=1) 
 110 patients included in analysis 
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Figure 2  
 
 
 
 
  
110 index cases33 (30.0%) cases guideline 
adherent 
One sEGD:        14 (42.4%)
Two sEGDs:     18 (23.4%)
Three sEGDs:        1 (3.0%)
77 (70.0%) cases guideline 
non-adherent
52 (67.5%) cases with 
irregular surveillance
One sEGD:        26 (33.8%)
Two sEGDs:      18 (23.4%)
Three sEGDs:         7 (9.1%)
Four sEGDs:  1 (1.3%)
25 (32.5%) cases with      
no surveillance
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